Sox12 Is a Cancer Stem-Like Cell Marker in Hepatocellular Carcinoma
2017
Song Zou, the People's Hospital of Ganzhou, Ganzhou, China | Chen Wang, the People's Hospital of Ganzhou, Ganzhou, China | Jiansheng Liu, the People's Hospital of Ganzhou, Ganzhou, China | Qun Wang, the Affiliated Hospital of Guilin Medical University, Guilin, China | Dongdong Zhang, the Affiliated Hospital of Guilin Medical University, Guilin, China | Shengnan Zhu, the Affiliated Hospital of Guilin Medical University, Guilin, China | Shengyuan Xu, the Affiliated Hospital of Guilin Medical University, Guilin, China | Mafei Kang, the Affiliated Hospital of Guilin Medical University, Guilin, China | Shaozhong He, the Affiliated Hospital of Guilin Medical University, Guilin, China
Recent studies on molecular carcinogenesis suggest that the chemo-resistance of some cancers is largely due to presence of cancer stem cells (CSCs), which affect the chemotherapy outcome for hepatocellular carcinoma (HCC). However, currently no consensus on a CSC phenotype in HCC has been obtained. Here, we examined Sox12 as a novel CSC marker in HCC. Sox12+ versus Sox12− cells were purified from HCC cell lines. The Sox12+ cells were compared with Sox12− HCC cells for tumor sphere formation, chemo-resistance, tumor formation after serial adoptive transplantations in nude mice, and the frequency of developing distal metastasis. We found that compared to Sox12− HCC cells, Sox12+ HCC cells generated significantly more tumor spheres in culture, were more chemo-resistant to cisplatin, were detected in circulation more frequently, and formed distal tumor more frequently. Moreover, Sox12 appeared to functionally contribute to the stemness of HCC cells. Thus, we conclude that Sox12 may be a novel marker for enriching CSCs in HCC.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Korea Agricultural Science Digital Library
